The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment

Hellenic Journal of Nuclear Medicine

Volumn 11, Issue 3, 2008, Pages 160-163

  Eftekhari, Mohammad ^a,b   Asadollahi, Abolfazl ^a   Beiki, Davood ^a   Izadyar, Sina ^b   Gholamrezanezhad, Ali ^a   Assadi, Majid ^a   Fard Esfahani, Armaghan ^a   Fallahi, Babak ^a   Takavar, Abbas ^a   Saghari, Mohsen ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; Differentiated thyroid carcinoma; Levothyroxine; Osteoporosis; Postmenopausal women

Indexed keywords

IODINE 131; LEVOTHYROXINE;

ADULT; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HIP; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; POSTMENOPAUSE; POSTOPERATIVE CARE; PREMENOPAUSE; RISK ASSESSMENT; SIDE EFFECT; THYROID CARCINOMA; THYROID SURGERY; TREATMENT DURATION;

ADENOCARCINOMA, FOLLICULAR; BONE DENSITY; CARCINOMA, PAPILLARY; CROSS-SECTIONAL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; OSTEOPOROSIS; PREMENOPAUSE; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; THYROXINE;

EID: 60849104445     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998; 83: 2638-2648.
2. Pacini F, Lari R, Mazzeo S et al. Diagnostic value of a single thyroglobulin determination on and off thyroid suppressive treatment in the follow up patients with differentiated thyroid cancer. Clin Endocrinol 1985; 23: 405-411.
3. Mazokopakis EE, Starakis IK, Papadomanolaki MG et al. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy. Curr Med Res Opin 2006; 22: 1369-1373.
4. Kamer I, Hrgović Z, Sijanović S et al. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur J Med Res 2005; 10: 480-488.
5. Khmara IM, Tolkachev IV. Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy. Klin Med (Mosk) 2005; 83: 61-65.
6. Heijckmann AC, Huijberts MS, Geusens P et al. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endociinol 2005; 153: 23-29.
7. Faber J, Jensen IW, Petersen L et al. Normalization of serum thyrotropin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol 1998; 48: 285-290.
8. Kisakol G, Kaya A, Gonen S, Tunc R. Bone and calcium metabolism in subdinical autoimmune hyperthyroidism and hypothyroidism Endocr J 2003; 50: 657-661.
9. Gurlek A, Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999; 9: 539-543.
10. De Menis E, Da Rin G, Roiter I et al. Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma. Horm Res 1992; 37: 217-220.
11. Belaya ZE, Melnichenko GA, Rozhinskaya LY et al. Subclinical hyperthyroidism of variable etiology and its influence on bone in postmenopausal women. Hormones 2007; 6: 62-70.
12. Heemstra KA, Hamdy NA, Romijn JA, Smit JW. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 2006; 16: 583-591.
13. Kung AWC. The effect of thyroid hormone on bone metabolism and osteoporosis. J Hong Kong Med Assoc 1994; 46; 247-251.
14. Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 1996; 81: 1232-1236.
15. Reverter JL, Holgado S, Alonso N et al. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocr Relat Cancer 2005; 12: 973-981.
16. Müller CG, Bayley TA, Harrison JE, Tsang R. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid 1995; 5: 81-87.
17. Guo CY, Weetman AP, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol 1997; 46: 301-307.
18. Taelman P, Kaufman JM, Janssens X et al. Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goitre treated with thyroid hormone. Clin Endocrinol 1990; 33: 107-117.
19. Ross DS, Neer RM, Ridgway EC, Daniels GH. Subdinical hyperthyroidism and reduced bone mineral density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987; 82: 1167-1170.
20. Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of levothyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991; 72: 1184-1188.
21. McDermott MT, Kidd GS, Blue P et al. Reduced bone mineral content in total thyroidectomized patients: possible effect of calcitonin deficiency. J Clin Endocrinol Metab 1983; 56: 936-939.
22. Langdahl BL, Loft AG, Moller N et al. Skeletal responsiveness to thyroid hormone is not altered at menopause. Bone 1996; 19: 557-564.
23. Greenspan SL, Greenspan FS, Resnick NM et al. Skeletal integrity in pre-menopausal and postmenopausal women receiving long-term L-thyroxine therapy. Am J Med 1991; 91: 5-14.
24. Marcocci C, Golia F, Bruno-Bossio G et al. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in pre-menopausal women. J Clin Endocrinol Metab 1994; 78: 818-823.
25. Paul TL, Kerrigan J, Kelly AM et al. Long-term L-thyroxine is associated with decreased hip bone density in premenopausal women. JAMA 1988; 259: 3137-3141.
26. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990. 113: 265-269.
27. Burman KD. Is long-term levothyroxine therapy safe? Arch Intern Med 1990; 150: 2010-2013.
28. Utiger RD. Therapy of hypothyroidism: when are changes needed? N Engl J Med 1990; 323: 126-127.